Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

529
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

664
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
664
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

555
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
555
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

599
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
599
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

533
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
533
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

423
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional cookies with improved flavor, digestibility and shelf life via application of Camellia seed oil-based emulsion gel for grape seed polyphenol delivery.

Food chemistry: X·2026
Same author

Ultra-narrowband hot-electron photodetection with Friedrich-Wintgen bound states in the continuum.

Optics express·2026
Same author

A tailorable interfacial dual-binding strategy using rosmarinic acid for the oxidative stabilization of rice bran oil bodies.

Journal of the science of food and agriculture·2026
Same author

MyH7 antisense long non-coding RNA promotes the formation of slow-twitch fibers through stabilizing MyH7 mRNA.

International journal of biological macromolecules·2026
Same author

Specular highlight suppression based on full polarization imaging.

Applied optics·2026
Same author

Application of a Modified In Situ Perfusion Model to Quantify Intestinal Drug Excretion and Transporter-Mediated Interactions after Intravenous Administration.

The AAPS journal·2026

Related Experiment Video

Updated: Mar 3, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease

Qiang Tan1, Shuangyue Zhang, Xiaoyi Zou

  • 1Department of Cardiology, Qinhuangdao First Hospital; Qinhuangdao-People's Republic of China. qhdtanqiang@aliyun.com.

Anatolian Journal of Cardiology
|April 22, 2017
PubMed
Summary

Fluvastatin therapy did not prevent atrial fibrillation (AF) progression but significantly reduced AF recurrence and cardiac dysfunction. This suggests potential benefits in managing AF through anti-inflammatory effects and improved endothelial progenitor cells (EPCs).

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Related Experiment Videos

Last Updated: Mar 3, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) poses a significant risk for stroke and heart failure.
  • Understanding therapeutic interventions to manage AF progression and recurrence is crucial.
  • Statins are known for their lipid-lowering and pleiotropic effects.

Purpose of the Study:

  • To investigate the efficacy of fluvastatin in preventing the progression of paroxysmal atrial fibrillation (AF) to permanent AF.
  • To assess the impact of fluvastatin on the recurrence rate of AF.
  • To evaluate fluvastatin's effect on cardiac dysfunction, stroke, and mortality.

Main Methods:

  • A prospective, randomized case-control study involving 118 patients with paroxysmal AF.
  • Patients were assigned to either fluvastatin therapy (n=61) or a control group (n=57) for 24 months.
  • Primary endpoint: progression to permanent AF. Secondary endpoints: AF recurrence, cardiac dysfunction, stroke, and death.

Main Results:

  • No significant difference in AF progression to permanent AF between the fluvastatin and control groups (8.19% vs. 12.51%).
  • Fluvastatin significantly reduced AF recurrence (24.59% vs. 49.12%) and cardiac dysfunction (6.55% vs. 19.29%).
  • Lower C-reactive protein (CRP) and homocysteine (HCY) levels, and increased endothelial progenitor cells (EPCs) were observed in the fluvastatin group.

Conclusions:

  • Fluvastatin therapy does not prevent the progression of paroxysmal AF to permanent AF.
  • Fluvastatin effectively decreases the recurrence rate of AF and reduces cardiac dysfunction.
  • The observed benefits may be attributed to fluvastatin's anti-inflammatory properties and its positive impact on circulating EPCs.